HIV Drug Development--Emerging Technologies

HIV Drug Development--Emerging Technologies published by Technical Insights, Inc. in June, 2006. This report price starts from US $ 6000.

Introduction

Abstract

This Frost & Sullivan research service titled HIV Drug Developments - Emerging Technologies provides information on HIV drugs, vaccines, and the microbicides sector. The study focuses on novel, emerging technologies and novel applications of existing technologies in context with HIV drug development. It also covers advances in research and development (R&D), product development, and regulatory aspects specifically related to the emerging technologies in HIV drug development.

This analysis is available through our Technical Insights Growth Partnership Services program. With this program, clients receive industry-leading market research such as this, along with technical and econometric data as well as many interactive features including Analyst Inquiry Time and Client Councils.

Frost & Sullivan Growth Partnership Service

Based on extensive and in-depth research, real-world consulting work, and new theories tested in hundreds of companies across many industries, Frost & Sullivan has evolved its Growth Partnership Services (GPS) program that provides established and emerging firms with powerful growth visions. Moving beyond token mission statements, GPS provides an actionable vision to growth consulting partners by illustrating how key intelligence and strategic research based on defined goals can guide day-to-day behavior and overall company direction. The foundation of Frost & Sullivan's GPS includes:

• Assisting companies to reach their full potential in the core business
• Providing growth strategies to help companies expand into related businesses
• Preemptively redefining the core business during market turbulence
• Applying the Frost & Sullivan framework to identify and address common mistakes resulting from misaligned corporate strategies
• Recommending growth management strategies through continuous partnership

To maximize the potential for growth within a firm's internal and external environment, Frost & Sullivan consultants can facilitate the creation of strategic programs that deliver improved market success. Frost & Sullivan's strengths lie in combining strategic understanding with market expertise and applying these with absolute commitment to its clients' growth.

Table of Contents

1. Executive Summary

• 1. Introduction
  • 1. Introduction to HIV
  • 2. Prevalence
• 2. Scope and Methodology
  • 1. Scope
  • 2. Methodology

2. Technology and Applications View Point

• 1. Technology Primer
  • 1. Drugs
  • 2. Vaccines
  • 3. Microbicides
  • 4. The Red Ribbon Project
• 2. Trends and Important Clinical Trials
  • 1. In Development
  • 2. Global Scenario
  • 3. Important Clinical Trials

3. Technology Adoption Factor Analysis

• 1. Drivers and Challenges
  • 1. Drivers
  • 2. Challenges
• 2. Regulatory Hurdles and Funding
  • 1. Regulatory Hurdles
  • 2. Funding

4. Technological Advancements--Drugs

• 1. Technological Advancements--Companies
  • 1. Viral Entry Inhibitor-Based Monoclonal Antibody for HIV Treatment--USA
  • 2. Novel Entry Inhibitor-Based Drug for Protecting Healthy Cells from HIV Infection--Canada
  • 3. Innovative Entry Inhibitor-Based Drug Pipeline as HIV Therapeutics--USA
  • 4. Nucleoside Reverse Transcriptase Inhibitor Drug-Based Therapy for Prevention of HIV Infection--USA
  • 5. Drug Preventing the Action of Enzyme Required for Replication--USA
  • 6. Entry Inhibitor-Based Drug for Prevention of HIV Infection--USA
  • 7. Reverse Transcriptase Enzyme Inhibitor for Prevention of Fresh Infection of Cells--USA
  • 8. Telomerase-Based Drug for Enhancing Antiviral Activity Targeting HIV Infection--China
• 2. Technological Advancements--Research Institutions
  • 1. Dynamic Host-Viral Interactions to Aid in Drug Development
  • 2. Scientists Reveal the Molecule Involved in HIV Integration with Host Genetic Component

5. Technological Advancements--Vaccines and Microbicides

• 1. Technological Advancements in Companies--Vaccines
  • 1. AdVac-Based Vaccines to Tackle HIV--Netherlands
  • 2. DNA-Based Vaccine for HIV--U.S.
  • 3. Monoclonals for Blocking HIV--U.S.
  • 4. Plant-Based HIV vaccines--U.S.
  • 5. Therapore Technology-Based HIV Vaccine--U.S.
  • 6. Dendritic Cell Technology for AIDS Vaccine--United Kingdom
• 2. Technological Advanvements in Companies--Mictrobicides
  • 1. Gel Based Microbicide for the Prevention of HIV Infection--Canada
  • 2. Microbicide Based Gel Tackling HIV Infection--Australia
  • 3. Microbicide-Based Gel for Counter-Attacking HIV Infection--U.S.
  • 4. Oligonucleotide-Based Microbicide for HIV Prevention--U.S.
• 3. Research Institutions
  • 1. Vaccine to Tackle HIV Using Genetically Modified Tobacco--UK
  • 2. Retroviral-Based Approach for Interfering with HIV Replication--India
  • 3. Liposome-Based Adjuvant for Development of Vaccines--India
  • 4. Adenovector-Based Vaccine to Target HIV--U.S.
  • 5. Novel Targets for Antiviral Approach against HIV--India
  • 6. Plant-Based Vaccine for HIV--Russia

6. Key Patents; Contacts; and Glossary

• 1. Key Patents
  • 1. Patents--Drugs and Developments
  • 2. Patents--Vaccines
• 2. Contacts and Glossary
  • 1. Contacts
  • 2. Glossary

7. Frost & Sullivan 2006 Science & Technology Awards

• 1. Technology Innovation Award
  • 1. Award Description
  • 2. Award Recipient
• 2. Excellence in Technology Award
  • 1. Award Description.
  • 2. Award Recipient
• 3. Excellence in Research Award
  • 1. Award Description
  • 2. Award Recipient

8. Decision Support Database

• 1. Database Tables
  • 1. Number of Biotech Companies (1999-2006)
  • 2. Government Investment in Biotech R&D (1999-2006)
  • 3. Private Investment in Biotech (1999-2006)
  • 4. HIV Prevalence (1999-2006)
  • 5. AIDS Mortality (1999-2006)

Related Reports